Brief: Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection
19/02/2026 16:44
Feb 19 (Reuters) - Eisai Co Ltd 4523.T: EISAI CO LTD: CO & BIOGEN CANADA DISAGREE WITH CANADA'S DRUG AGENCY THAT AGENCY WILL NOT RECOMMEND LEQEMBI FOR PUBLIC REIMBURSEMENT IN CANADA EISAI CO LTD: WILL CONTINUE TO PURSUE ALL POSSIBLE OPTIONS FOR PUBLIC REIMBURSEMENT IN CANADA Source text: ID:nCNWDVN13a Further company coverage: 4523.T ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China